CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-25 | Daly James M Director | Grant or award · Stock Option (Right to Buy) | +1,105 | 1,105 | ||
| 2024-06-25 | Levy Richard S Director | Grant or award | +714 | 11,012 | ||
| 2024-06-25 | Levy Richard S Director | Grant or award · Stock Option (Right to Buy) | +1,105 | 1,105 | ||
| 2024-06-25 | FRIEDMAN PAUL A Director | Grant or award | +714 | 186,449 | ||
| 2024-06-25 | FRIEDMAN PAUL A Director | Grant or award · Stock Option (Right to Buy) | +1,105 | 1,105 | ||
| 2024-06-25 | BAKER BROS. ADVISORS LP Director | Grant or award | +1,428 | 187,407 | ||
| 2024-06-25 | BAKER BROS. ADVISORS LP Director | Grant or award | +1,428 | 1,794,831 | ||
| 2024-06-25 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Options (right to buy) | +2,210 | 2,210 | ||
| 2024-06-25 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Options (right to buy) | +2,210 | 2,210 | ||
| 2024-06-14 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +1,900 | $87.09 | $165K | 7,400 |
| 2024-06-14 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,900 | $280.00 | $532K | 5,500 |
| 2024-06-14 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −1,900 | 10,350 | ||
| 2024-06-12 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +2,000 | $87.92 | $176K | 7,500 |
| 2024-06-12 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −2,000 | $285.00 | $570K | 5,500 |
| 2024-06-12 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −2,000 | 15,200 | ||
| 2024-06-11 | CRAVES FRED B Director | Gift | −39,000 | 374,362 | ||
| 2024-06-11 | CRAVES FRED B Director | Gift | −45,852 | 11,210 | ||
| 2024-05-21 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,036 | $231.34 | $240K | 5,500 |
| 2024-05-14 | CRAVES FRED B Director | Option exercise 10b5-1 | +10,000 | $100.45 | $1.0M | 423,362 |
| 2024-05-14 | CRAVES FRED B Director | Option exercise 10b5-1 | +12,489 | $105.08 | $1.3M | 435,851 |
Page 29 of 82 · 1,629 trades